Castle Biosciences Aktie

Kaufen

Verkaufen

30,00 EUR +0,40 EUR +1,35 %

17:37:06

FSE

35,23 USD +0,48 USD +1,38 %

17:36:45

BTT

Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Bei einem anderen Broker handeln

Marktkap.834,18 Mio. EUR

KGV42,74Div. Rendite0,00%

WKNA2PNH3

ISINUS14843C1053

SymbolCSTL

Castle Biosciences Aktien News

Sortieren:Datum Meistgelesen

06.01.25BusinesswireCastle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test

19.12.24BusinesswireCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

20.11.24BusinesswireCastle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference

19.11.24BusinesswireCastle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year

08.11.24BusinesswireCastle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting

07.11.24BusinesswireCastle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test

06.11.24BusinesswireUse of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024

28.10.24BusinesswireCastle Biosciences to Participate in Upcoming Investor Conferences

16.10.24BusinesswireRecent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential

14.10.24BusinesswireCastle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024

11.10.24BusinesswireCastle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin

02.10.24BusinesswireCastle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas

16.09.24BusinesswireCastle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year

11.09.24BusinesswireDecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms

05.09.24BusinesswireStudy Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma

28.08.24BusinesswireCastle Biosciences to Participate in Upcoming Investor Conferences

30.07.24BusinesswireCastle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference

22.07.24BusinesswireCastle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma

15.07.24BusinesswireCastle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024

11.07.24BusinesswireCastle Biosciences Honored with Top Workplaces Awards

20.06.24BusinesswireCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14.06.24BusinesswireCastle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner

15.05.24BusinesswireCastle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference

10.05.24BusinesswireCastle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution”

30.04.24BusinesswireCastle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

11.04.24BusinesswireCastle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024

10.04.24BusinesswireCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

10.04.24BusinesswireCastle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year

04.04.24BusinesswirePresentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

02.04.24BusinesswireCastle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

25.03.24BusinesswireCastle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year

12.03.24BusinesswireCastle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

08.03.24BusinesswireCastle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

07.03.24BusinesswireIn Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups

28.02.24BusinesswireCastle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

26.02.24BusinesswireStudy Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging

07.02.24BusinesswireCastle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024

14.01.24BusinesswireCastle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®

09.01.24BusinesswireCastle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report

20.12.23BusinesswireCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Castle Biosciences News

Castle Biosciences News: auf dieser Seite finden Sie alle Castle Biosciences News und Nachrichten zur Castle Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Castle Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Castle Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.